{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/asthma/management/follow-up/","result":{"pageContext":{"chapter":{"id":"2878c5f8-3e3f-52c8-a9bd-7988906b6f99","slug":"follow-up","fullItemName":"Scenario: Follow-up","depth":2,"htmlHeader":"<!-- begin field 2d1178f2-ec38-4dd1-b47b-a6be0107cf8f --><h2>Scenario: Follow-up</h2><!-- end field 2d1178f2-ec38-4dd1-b47b-a6be0107cf8f -->","summary":"Covers the appropriate follow-up of children and adults who have asthma.","htmlStringContent":"<!-- begin item 62e8b32d-7874-4cb1-9b5f-a6be0107cf35 --><!-- begin field ba4c532c-2492-476c-b74e-acd900ac40bb --><p>From age 1 month onwards.</p><!-- end field ba4c532c-2492-476c-b74e-acd900ac40bb --><!-- end item 62e8b32d-7874-4cb1-9b5f-a6be0107cf35 -->","topic":{"id":"d631356f-d3a3-51fb-807c-5517c470a5af","topicId":"2a0a90e6-1c4e-4b6a-9ce2-3379dd122594","topicName":"Asthma","slug":"asthma","lastRevised":"Last revised in October 2020","chapters":[{"id":"c7185669-75fd-5c6e-b105-63a3237634ac","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"9fe1ab10-4b4d-5ba8-9ef0-00631cd00ea4","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"770d55df-2c61-5d1e-83d9-92b12ccae96a","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"d2031db2-44fd-55bb-b5c8-d085b387747a","slug":"changes","fullItemName":"Changes"},{"id":"a993bde1-1ac8-529e-8a3e-201a8c082ab2","slug":"update","fullItemName":"Update"}]},{"id":"eae8fe92-3941-512e-bcc6-f1e15157c1ae","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"8e125759-cd9d-510d-9659-3c2e77baa755","slug":"goals","fullItemName":"Goals"},{"id":"a6c91cd5-1ce2-5c60-86cc-341a9dccf3d4","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"a5746054-2f36-5a42-9e7c-7af9107ad99b","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"5fd19cd9-6ac7-54c8-89be-817d58e41309","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"f7339086-c653-53dd-990c-6d470fa223b8","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"f43b79db-3c62-58ee-bb70-932e6613eea6","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"0d12a387-5436-5c75-92c0-189cb391ec7a","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"8fbe04ed-5fd7-54c9-be84-6c959f75af3b","slug":"definition","fullItemName":"Definition"},{"id":"5cbe6206-f80c-5a71-8e4d-a4d44e392874","slug":"prevalence","fullItemName":"Prevalence"},{"id":"2fb588ab-6181-5aec-8a4a-fb368098329d","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"b786654f-5e6e-5e5f-9ead-abaca7f99ba5","slug":"prognosis","fullItemName":"Prognosis"},{"id":"c0b65c0b-957e-538e-83e9-5b4af2d8e6dd","slug":"complications","fullItemName":"Complications"}]},{"id":"574c6193-f36f-5bf7-946a-d8c688476131","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"351773e5-286c-5560-8402-79c2d92d4aa6","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"053272da-fea9-5df6-842a-0de682896aaf","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"7b632c20-012f-590e-a01e-cda5715d6f14","fullItemName":"Management","slug":"management","subChapters":[{"id":"f95fb73f-b749-53a5-b857-4d2bb9945667","slug":"newly-diagnosed-asthma","fullItemName":"Scenario: Newly-diagnosed asthma"},{"id":"2878c5f8-3e3f-52c8-a9bd-7988906b6f99","slug":"follow-up","fullItemName":"Scenario: Follow-up"},{"id":"2458c073-8efb-5a81-8bc4-9a543deab17d","slug":"acute-exacerbation-of-asthma","fullItemName":"Scenario: Acute exacerbation of asthma"},{"id":"45a1b06c-1e5d-56b4-8da7-a8abf4f6c7cc","slug":"covid-19","fullItemName":"Scenario: COVID-19"}]},{"id":"fb9dc424-4306-54a1-b06b-1b01273ac473","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"52940123-8084-55c3-b593-cc9fe50daf8f","slug":"azithromycin","fullItemName":"Azithromycin"},{"id":"5eb1288c-29af-59c1-b623-bd0010732835","slug":"beta-2-agonists","fullItemName":"Beta-2 agonists"},{"id":"dc8f7545-ff7a-5bf1-8ac8-95161137fac5","slug":"inhaled-corticosteroids","fullItemName":"Inhaled corticosteroids"},{"id":"4d715496-c821-52e3-8ea0-d05cfb33d3eb","slug":"oral-corticosteroids","fullItemName":"Oral corticosteroids"},{"id":"d8174f33-d787-5076-88b5-f4c67df93128","slug":"leukotriene-receptor-antagonists","fullItemName":"Leukotriene receptor antagonists"},{"id":"a556cd4f-1851-52fd-a993-34e977a27fd2","slug":"muscarinic-agents","fullItemName":"Muscarinic agents"},{"id":"0cea3b69-b77b-505e-bded-6fceaca145df","slug":"theophylline","fullItemName":"Theophylline"},{"id":"550429f1-7cab-5f16-b476-e479d8084c03","slug":"cromones","fullItemName":"Cromones"}]},{"id":"76b3dfce-ba54-5456-a259-79b345a5e064","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"e31b3681-17cc-5ff2-ba28-d3b1fcb0a82c","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"2bcf3eeb-fd2e-5d40-a52f-da626afbbe01","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"14ea4312-4846-5381-a82c-dc6b03a60d04","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"e4987bc8-0a78-59eb-bfda-f9de7c9ee182","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"be4f3045-8192-53b7-81a3-b460bb2218bc","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"82ae443c-942c-5053-a988-38bce8dec570","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"efdf3cf8-dee5-5351-9d2d-346b4fdf9faf","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"7b632c20-012f-590e-a01e-cda5715d6f14","slug":"management","fullItemName":"Management"},"subChapters":[{"id":"c33d264c-6acc-50e7-9f9d-ed2f65d95854","slug":"how-should-i-follow-up-a-person-with-asthma","fullItemName":"How should I follow-up a person with asthma?","depth":3,"htmlHeader":"<!-- begin field 353e7fdb-daf9-4abe-82cd-a6be0107cf94 --><h3>How should I follow-up a person with asthma?</h3><!-- end field 353e7fdb-daf9-4abe-82cd-a6be0107cf94 -->","summary":null,"htmlStringContent":"<!-- begin item 045c7ab2-0640-464c-b6e7-a6be0107cf94 --><!-- begin field 7e5fce9e-5997-41fa-94cd-a6be0107cf94 --><ul><li><strong>People with asthma should be followed up at least annually, to determine whether their treatment needs to be changed. </strong>Closer monitoring of people with poor lung function, severe asthma and/or a history of an asthma attack within the last year should be considered.</li><li>Monitor asthma control at each review in anyone aged 5 years and over using either spirometry or peak flow variability testing.</li><li>Except in specialist asthma clinics, the routine use of FeNO testing to monitor asthma in adults or children is not recommended.</li><li>Observe and give advice on the person's inhaler technique:<ul><li>At every consultation relating to an asthma attack.</li><li>When there is deterioration in asthma control.</li><li>When the inhaler device is changed.</li><li>At every annual review.</li><li>If the person asks for it to be checked.</li></ul></li><li><strong>In all people, monitor:</strong><ul><li>Number of asthma attacks, oral corticosteroid use, time off school/nursery/work due to asthma.</li><li>Nocturnal symptoms.</li><li>Adherence (which can be assessed by reviewing prescription refill frequency).</li><li>Possession of/use of a self-management plan/written personalised asthma action plan.</li><li>Exposure to tobacco smoke.</li></ul></li><li><strong>In children, specific factors that should be monitored and recorded include:</strong><ul><li>Symptom score (best assessed using the <a href=\"http://www.asthma.com/additional-resources/childhood-asthma-control-test.html\" data-hyperlink-id=\"ee67a13d-0cc2-42ff-a5bc-a8f7015a58ca\">Childhood Asthma Control Test,</a> or <a href=\"https://www.qoltech.co.uk/acq.html\" data-hyperlink-id=\"4924c7ac-fecb-482e-b714-a8f7015a59da\">Asthma Control Questionnaire</a>).<ul><li>Additionally, assess asthma control using closed questions such as \"do you use your blue inhaler (reliever) every day?\"</li><li>Whenever practicable, children should be asked about their own symptoms, do not rely solely on parental report.</li></ul></li><li>Growth (height and weight centiles).</li></ul></li><li><strong>In adults, specific factors that should be monitored and recorded include:</strong><ul><li>Symptomatic asthma control (best assessed using directive questions such as <a class=\"topic-reference internal-reference\" href=\"/topics/asthma/management/follow-up/#the-royal-college-of-physicians-3-questions\">The Royal College of Physicians 3 Questions</a> or the <a href=\"https://www.asthma.com/content/dam/NA_Pharma/Country/US/Unbranded/Consumer/Common/Images/MPY/documents/80108R0_AsthmaControlTest_ICAD.pdf\" data-hyperlink-id=\"2b380e42-e788-4ec8-ba8e-a8f7015a5a1b\">Asthma Control Test</a>, or <a href=\"https://www.qoltech.co.uk/acq.html\" data-hyperlink-id=\"c8437fde-c451-46c7-bd1d-a8f7015a5a4f\">Asthma Control Questionnaire</a>).<ul><li>Additionally, assess asthma control using closed questions such as “how many days a week do you use your reliever (blue) inhaler?”</li></ul></li><li>Lung function.</li><li>Bronchodilator overuse, especially more than 12 short-acting beta-2 agonist (SABA) inhalers per year.</li><li>Smoking status.</li><li>The possibility of occupational asthma.</li></ul></li><li><strong>Assess the risk of future asthma attacks to identify people at increased risk.</strong><ul><li>In adults, factors associated with: <ul><li><strong>Greatly increased risk</strong> include history of previous asthma attacks.</li><li><strong>Moderately increased risk</strong> include poor control, inappropriate or excessive use of SABAs.</li><li><strong>Slightly increased risk </strong>include older age, female, reduced lung function, obesity, smoking, and depression.</li></ul></li><li>In children, factors associated with:<ul><li><strong>Greatly increased risk</strong> include a history of previous asthma attacks, and persistent asthma symptoms.</li><li><strong>Moderately increased risk</strong> include sub-optimal drug regimen, comorbid/atopic allergic disease, low-income family, and Vitamin D deficiency. </li><li><strong>Slightly increased risk </strong>include younger age, exposure to environmental tobacco smoke, obesity, and low parental education.</li></ul></li></ul></li><li><strong>People on long-term steroid tablets (for example, longer than three months) or requiring frequent courses of steroid tablets (for example three to four per year) should be offered monitoring of:</strong><ul><li>Blood pressure.</li><li>Urine or blood sugar (measured by HbA1c).</li><li>Cholesterol.</li><li>Bone mineral density.</li><li>Vision (to assess for cataracts and glaucoma). </li></ul></li><li><strong>If medication is adjusted, review the response to treatment in 4 to 8 weeks.</strong></li></ul><h4>Oral macrolides</h4><ul><li>For people 50–70 years of age who have ongoing symptoms, despite high-dose inhaled steroids, who have suffered one exacerbation requiring oral steroids in the previous year; prophylactic treatment with oral macrolide therapy could be considered to reduce the possibility of exacerbation frequency.</li><li>Treatment with azithromycin 500 mg three times per week, should be considered for a minimum of 6–12 months to assess evidence of efficacy in reducing exacerbations.</li><li>This treatment should not be offered as a way to reduce oral steroid dose.</li><li><strong>Before commencing prophylactic oral macrolides</strong><ul><li class=\"MsoNormal\">Consider referral to a respiratory specialist or specialist asthma service. </li><li class=\"MsoNormal\">Ensure optimisation of other asthma therapies, including establishing good adherence to inhaled therapies. </li><li class=\"MsoNormal\">ECG (electrocardiogram) should be performed to assess QTc interval.</li><li class=\"MsoNormal\">Perform baseline liver function tests.</li><li class=\"MsoNormal\">Patients should be counselled about potential adverse effects, including gastrointestinal upset, hearing and balance disturbance, cardiac effects, and microbiological resistance.</li></ul></li><li class=\"MsoNormal\"><strong>If oral macrolide therapy is prescribed</strong> ongoing treatment should be guided by the clinical response, including exacerbation frequency, variation of symptoms and quality of life.</li><li class=\"MsoNormal\">If adverse gastrointestinal effects occur at this higher dose of azithromycin clinicians can consider a dose reduction to 250 mg three times per week.</li><li class=\"MsoNormal\">Liver function tests should be checked 1 month after starting treatment and then every 6 months. An ECG should be performed 1 month after starting treatment to check for new QTc prolongation. If present, treatment should be stopped.</li><li class=\"MsoNormal\">If the desired clinical outcome is achieved, the possibility of breaks in therapy can be considered to reduce the treatment burden for patients.</li></ul><!-- end field 7e5fce9e-5997-41fa-94cd-a6be0107cf94 --><!-- end item 045c7ab2-0640-464c-b6e7-a6be0107cf94 -->","subChapters":[{"id":"d858e8e1-e4cc-5f18-bdc1-5b247866ca6a","slug":"the-royal-college-of-physicians-3-questions","fullItemName":"The Royal College of Physicians 3 Questions","depth":4,"htmlHeader":"<!-- begin field 6e2cef1b-fffd-4e5b-8940-a7a700c442cb --><h4>The Royal College of Physicians 3 Questions</h4><!-- end field 6e2cef1b-fffd-4e5b-8940-a7a700c442cb -->","summary":null,"htmlStringContent":"<!-- begin item d8eac3dc-356d-439a-9658-a7a700c440ce --><!-- begin field de016cf2-8104-429c-a016-a7a700c442cb --><ul><li><strong>The 'Royal College of Physicians (RCP) 3 questions' is simple to use in every day clinical practice, but has not been validated in children.</strong></li><li>Answering 'no' to all three questions is consistent with controlled asthma. The three questions are:<ul><li>Have you had difficulty sleeping because of your asthma symptoms (including cough)?</li><li>Have you had your usual asthma symptoms during the day (e.g. cough, wheeze, chest tightness, or breathlessness)?</li><li>Has your asthma interfered with your usual activities (e.g. housework, work, school)?</li></ul></li></ul><!-- end field de016cf2-8104-429c-a016-a7a700c442cb --><!-- end item d8eac3dc-356d-439a-9658-a7a700c440ce -->","subChapters":[]},{"id":"c3bf5f7a-c304-53e1-9b59-0400bdfbe22f","slug":"basis-for-recommendation-a9c","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 9a59ef93-9b14-447f-bc67-a6be0107cf98 --><h4>Basis for recommendation</h4><!-- end field 9a59ef93-9b14-447f-bc67-a6be0107cf98 -->","summary":null,"htmlStringContent":"<!-- begin item a9caa51d-275b-4563-ad2b-a6be0107cf98 --><!-- begin field 10fd0bd5-0c6f-4913-9572-a6be0107cf98 --><p>The information on how to follow-up a person with asthma is based on expert opinion in the British Thoracic Society (BTS) and Scottish Intercollegiate Guidelines Network (SIGN) <em>British guideline on the management of asthma </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/asthma/references/\">BTS/SIGN, 2019</a>], and<em> </em>the National Institute for Health and Care Excellence Guideline <em>Asthma: diagnosis, monitoring and chronic asthma management </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/asthma/references/\">NICE, 2017</a>].</p><p class=\"MsoNormal\">The recommendation to consider oral macrolides in people 50–70 years of age who have ongoing symptoms and need oral steroids for an exacerbation in the previous year is based on the <em>British Thoracic Society Guideline for the use of long-term macrolides in adults with respiratory disease</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/asthma/references/\">Smith, 2020</a>]. </p><p class=\"MsoNormal\">The authors note that the advice relating to the age group reflects the population that had the highest quality evidence of macrolide therapy leading to a significant reduction in exacerbations.</p><!-- end field 10fd0bd5-0c6f-4913-9572-a6be0107cf98 --><!-- end item a9caa51d-275b-4563-ad2b-a6be0107cf98 -->","subChapters":[]}]}]}}},"staticQueryHashes":["3666801979"]}